Functionally, a lactylation-mimetic CREB1 mutant (K122Q) conferred robust resistance, enhancing cell survival and tumor growth, whereas a lactylation-deficient mutant (K122R) sensitized cells to cisplatin. This evidence concerns the gene CREB1 and neoplasm.